Statement: the primary trial recorded half as many patients vomiting as the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 4/20 (20.00%)   Diarrhea 1/20 (5.00%)   Nausea 1/20 (5.00%)   Sodium, serum-low (hyponatremia) 1/20 (5.00%)   Death - Disease progression NOS 1/20 (5.00%)   Dyspnea (shortness of breath) 1/20 (5.00%)   Hypoxia 1/20 (5.00%)
Secondary_evidence: Adverse Events 1:   Total: 39/39 (100.00%)   Febrile Neutropenia  1/39 (2.56%)   Heart failure  1/39 (2.56%)   Diarrhea  3/39 (7.69%)   Nausea/vomiting  4/39 (10.26%)   Mucositis  3/39 (7.69%)   Fatigue  4/39 (10.26%)   infection  3/39 (7.69%)   Urinary tract infection  2/39 (5.13%)   Musculoskeletal pain  6/39 (15.38%)   Syncope  1/39 (2.56%)   Insomnia  3/39 (7.69%)   Anxiety  2/39 (5.13%)